Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aim: To examine the real‐world cardiovascular effectiveness and safety associated with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment in older adults with type 2 diabetes. Materials and Methods: In this retrospective cohort study, older adults with type 2 diabetes (aged ≥65 years) were identified in the Korean National Health Insurance Service database from September 2014 to December 2016. In total, 408 506 new users of an SGLT2 inhibitor or DPP‐4 inhibitor were propensity score matched. Cox regression was used to estimate the hazard ratios (HR) and 95% confidence interval (CI) for outcomes of interest: hospitalization for heart failure (HHF), all‐cause death, myocardial infarction, stroke, diabetic ketoacidosis (DKA), bone fracture, severe hypoglycaemia, genital infection and urinary tract infection (UTI). Results: Compared with DPP‐4 inhibitors, new users of SGLT2 inhibitors had a lower risk of HHF (HR 0.86; 95% CI 0.76‐0.97), all‐cause death (HR 0.85; 95% CI 0.75‐0.98) and stroke (HR 0.86; 95% CI 0.77‐0.97), but a similar risk of myocardial infarction (HR 0.95; 95% CI 0.77‐1.19). The risks of DKA, bone fracture and severe hypoglycaemia were similar between both groups, although genital infection (HR 2.44; 95% CI 2.22‐2.67) and UTI (HR 1.05; 95% CI 1.00‐21.11) were more frequent among new users of SGLT2 inhibitors compared with DPP‐4 inhibitors. Conclusion: Our findings suggest that initiation of SGLT2 inhibitors offers cardiovascular disease protection and can be used safely in older adults with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“25 SD on the probability scale.(21) We set age, sex, index year, household income, prescribed medication, co-morbidities and frailty as confounding variables then used them to calculate propensity scores.”
MethodCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“was expected to be attributed to cardiovascular causes with type 2 diabetes.(8,9,45) Third, there is a possibility of residual confounding by unmeasured or uncontrolled confounders because this is an observational study that collected exposure information from a health insur-”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“was expected to be attributed to cardiovascular causes with type 2 diabetes.(8,9,45) Third, there is a possibility of residual confounding by unmeasured or uncontrolled confounders because this is an observational study that collected exposure information from a health insur-”
BackgroundCheol Seong, S., Kim, Y.-Y., Khang, Y.-H., Heon Park, J., Kang, H.-J., Lee, H., Do, C.-H., Song, J.-S., Hyon Bang, J., Ha, S., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw253 · Cited by 1,277
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274 · cited 1×
“Older adults with type 2 diabetes have a higher risk of cardiovascular disease (CVD) and mortality.(3) In addition, older adults are more prone to adverse drug reactions than younger adults because of multiple medication regimens (polypharmacy), co-morbidities and agerelated changes in pharmacokinetics and pharmacodyn…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 1×
“In addition, we used an active drug comparator, new-user design and propensity score matching with control of common confounding variables to improve the robustness of the study findings.(42) There are limitations, indicating that our results should be interpreted with caution.”
Method
Research works printed but not linked: 31
- 10.4093/dmj.2019.0067 · DOI
- 10.1007/s00592-015-0790-4 · DOI
- 10.1177/2042098615615472 · DOI · Paper page
- 10.1016/j.numecd.2014.05.012 · DOI
- 10.1016/S2213-8587(13)70050-0 · DOI · Paper page
- 10.1093/ageing/afz096 · DOI · Paper page
- 10.2337/dc19-1476 · DOI · Paper page
- 10.1016/j.numecd.2017.11.007 · DOI · Paper page
- 10.4093/dmj.2019.0137 · DOI · Paper page
- 10.1007/s00125-016-3971-y · DOI
- 10.1111/dom.12889 · DOI · Paper page
- Mitnitski A, 2017, Heterogeneity of human aging and its assessment, J Gerontol A Biol Sci Med Sci., 72, 877
- 10.1093/gerona/glr065 · DOI
- 10.1111/dom.13627 · DOI
- 10.1111/dom.13424 · DOI · Paper page
- 10.1016/j.jacc.2018.03.009 · DOI · Paper page
- 10.1111/dom.14025 · DOI
- 10.1161/CIRCULATIONAHA.117.031227 · DOI · Paper page
- 10.1016/j.jacc.2018.01.085 · DOI · Paper page
- 10.2337/diacare.27.3.699 · DOI · Paper page
- 10.1186/s12933-017-0575-x · DOI
- 10.1136/bmj.k119 · DOI · Paper page
- 10.1111/dom.13477 · DOI · Paper page
- 10.1136/bmj.l4772 · DOI · Paper page
- 10.1016/S2213-8587(20)30130-3 · DOI
- 10.1007/s00059-017-4668-9 · DOI
- 10.1111/dom.12825 · DOI · Paper page
- 10.1111/dom.13531 · DOI · Paper page
- 10.1111/dom.13820 · DOI · Paper page
- 10.4093/dmj.2013.37.4.233 · DOI
- 10.1186/s42444-019-0005-0 · DOI · Paper page
Cited by
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
“86) compared with DPP-4 inhibitors [53].”
BackgroundWu, C.-Y., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1705 · Cited by 139
Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
Scheen, A. J., & Bonnet, F. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101419 · Cited by 51
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
Dadwani, R. S., Wan, W., Skandari, M. R., & Huang, E. S. (2023) · MDM Policy & Practice · doi:10.1177/23814683231187566 · Cited by 8
Metadata
- Authors
- Han, S. J., Ha, K. H., Lee, N., & Kim, D. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-12-15
- Volume
- 23
- Issue
- 3
- Pages
- 682-691
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3109783871
- Cited by
- 86
- References
- 13
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study. https://app.cochat.ai/papers/10.1111/dom.14261
- The paper
- Han, S. J., Ha, K. H., Lee, N., & Kim, D. J. (2021). Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14261
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.